Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + R-CHOP versus R-CHOP in newly diagnosed DLBCL
jRCT2021220043Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised trial of epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: PFS. Started Mar 2023; status: active, not recruiting.
02
Drugs
epcoritamabrituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2021220043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220043.